Bli medlem
Bli medlem

Du är här


Bavarian Nordic A/S: Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 24 April 2014

KVISTGÅRD, Denmark - April 24, 2014
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General
Meeting with the results as follows:

* The Annual Report for 2013 was adopted. The Board of Directors' proposal to
transfer the Company's result to next year was also adopted.
* The General Meeting adopted a resolution to discharge the Board of
Directors and the Board of Management from their obligations.
* Gerard van Odijk, Claus Bræstrup, Anders Gersel Pedersen, Erik G. Hansen
and Peter Kürstein were re-elected to the Board of Directors. The Chairman
of the Board, Asger J. Aamund has chosen not to be nominated for
re-election. The Board of Directors constituted itself with Gerard van
Odijk as Chairman.
* Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as
* The proposal to extend the Board of Directors authorization to increase the
share capital of the Company until 30 June 2015 was adopted.
* The proposal to increase and extend the Board of Directors authorization
for issuing Warrants was adopted.
* The suggested remuneration of the Board of Directors for the current
financial year was approved.
* The Board of Directors was authorized to let the Company purchase its own
* The proposal to change the Company's corporate language to English was
* The proposal that future general meetings may be held in either Danish or
English as resolved by the Board of Directors, and that documents prepared
for use by general meetings may also be prepared in Danish or English as
resolved by the Board of Directors was approved.
* The proposal that the Company's annual reports and interim financial
reports going forward are only prepared in English was approved.
* The proposal to adopt new general guidelines for incentive remuneration of
the board and management in Bavarian Nordic A/S was approved.

Anders Hedegaard, President&CEO.

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored
Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information,

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.